StockNews.AI
VCYT
StockNews.AI
176 days

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

1. VCYT reported record Q4 revenue with exceptional testing revenue growth. 2. VCYT achieved its 10th consecutive quarter over 20% testing revenue growth.

Earnings
-14.99%Current Return
VS
-0.5%S&P 500
$39.3602/24 04:16 PM EDTEvent Start
$33.4602/25 10:47 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The record Q4 revenue and sustained growth highlight robust operational performance, which historically has led to upward price movements in biotech stocks. Previous periods of similar performance in diagnostic companies have driven investor optimism and share price gains.

How important is it?

The announcement’s emphasis on record revenue and consecutive growth quarters is highly significant for VCYT’s investor confidence and could drive future price appreciation.

Why Long Term?

The consistent testing revenue growth and record earnings suggest a strong long-term outlook for VCYT. Similar trends in the biotech sector have typically translated into prolonged market strength and sustained value appreciation.

Related Companies

EXAS
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte's chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant op.

Related News